公开(公告)号：US10899788B2

公开(公告)日：2021-01-26

申请号：US16311363

申请日：2017-06-20

Applicant: Stephane Bogen ,  David Dukhan ,  Guillaume Brandt ,  Claire Pierra Rouviere ,  Cyril B. Dousson ,  Francois-Rene Alexandre ,  MERCK SHARP & DOHME CORP. ,  IDENIX PHARMACEUTICALS LLC

Inventor： Stephane Bogen ,  David Dukhan ,  Guillaume Brandt ,  Claire Pierra Rouviere ,  Cyril B. Dousson ,  Francois-Rene Alexandre

IPC: C07H19/11 ,  A61P31/14 ,  C07H19/213 ,  A61K45/06 ,  A61K31/7072 ,  A61K31/7076

Abstract: The present invention relates to Cyclic Phosphate Substituted Nucleoside Compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein in A, B, R1, R2, R3, Q and V are as defined herein. The present invention also relates to compositions comprising a Cyclic Phosphate Substituted Nucleoside Compound, and methods of using the Cyclic Phosphate Substituted Nucleoside Compounds for treating or preventing HCV infection in a patient.

公开(公告)号：US10231986B2

公开(公告)日：2019-03-19

申请号：US14866759

申请日：2015-09-25

Applicant: Centre National De La Recherche Scientifique ,  Universite Montpellier 2 Sciences Et Techniques ,  Idenix Pharmaceuticals LLC

Inventor： David Dukhan ,  Christophe Claude Parsy ,  Gilles Gosselin ,  Jean-François Griffon ,  Guillaume Brandt ,  Cyril B. Dousson ,  Adel M. Moussa ,  Benjamin Alexander Mayes ,  Alistar James Stewart

IPC: C07H19/073 ,  C07H19/10 ,  C07H19/173 ,  C07H19/20 ,  A61K31/7072 ,  C07H17/02 ,  A61K31/7068 ,  A61K45/06 ,  A61K9/00 ,  A61K31/7076

Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2′-cyano, azido or amino nucleosides according to Formula 1001 or 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein Base, W, R1 and R2 are as described herein.

公开(公告)号：US10202411B2

公开(公告)日：2019-02-12

申请号：US15304506

申请日：2015-04-16

Applicant: IDENIX PHARMACEUTICALS LLC

Inventor： David Dukhan ,  Cyril B. Dousson ,  Gilles Gosselin ,  Jean-Laurent Paparin ,  Guillaume Brandt ,  Rachid Rahali ,  Aurelien Salanson ,  François-René Alexandre

IPC: A01N43/04 ,  A61K31/70 ,  C07H19/20 ,  C07H19/10 ,  C07H19/11 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K45/06 ,  A61K31/7064 ,  A61K31/708 ,  A61K31/7052 ,  A61K31/706

Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3′-substituted methyl or alkynyl nucleosides of Formula I: (I); or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, PD, RA, RB1, RB2, RC and Z are as defined herein.